Biotech Values

[jbog]

Dew

Some investors are under the impression that the FTC would merely require Teva to divest MNTA’s generic-Copaxone program, but it’s highly unlikely, IMO, that the FTC would acquiesce to such a mild remedy.

While it is somewhat farfetched, I wouldn't put it past Teva if they looked to buy Momenta and fund the whole transaction by selling Momenta's portion of the copaxone franchise to Sandoz.